Conditions We Treat

Our plasma-derived protein therapies are used to treat conditions in the following therapeutic areas:

Immune Deficiencies

Immune deficiencies are inherited disorders in which one or more components of the human immune system are deficient or not functioning properly. As a result, individuals with immune deficiencies are susceptible to a wide range of infections that can cause serious illness or, in severe cases, death. 

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Grifols produces an FDA-approved intravenous immune globulin (IVIG) for the treatment of a neurological condition, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), which causes progressive nerve damage and weakness in the arms and legs.

Alpha1-Antitrypsin (AAT) Deficiency

Alpha1-antitrypsin (AAT) deficiency, also known as Alpha-1, is a genetic (inherited) disorder that causes significant reduction in the naturally-occurring blood protein alpha1-antitrypsin. A low level of alpha1-antitrypsin allows certain enzymes to attack healthy tissues in the body, primarily in the lungs. To replace missing or reduced levels of this protein, physicians often prescribe an alpha1-proteinase inhibitor. Because this therapy augments or replaces AAT, it is known as augmentation therapy.

Blood Clotting Disorders

The human body typically maintains a balance of blood proteins that slow or stop blood flow (in the case of injury) and facilitate blood flow (to prevent blood clots).  Blood clotting disorders can disrupt this balance, resulting in blood clots or excessive bleeding (failure to clot).

  • Hereditary Antithrombin III (AT III) deficiency is a rare disorder that can increase the risk of blood clots, particularly during surgeries as well as pregnancy and childbirth.  A doctor may prescribe ATIII therapy for patients with heredity ATIII deficiency in connection with a surgical procedure, or when they suffer from a thromboembolism.
  • Hemophilia is a genetic disorder characterized by the deficiency or absence of one of the blood proteins responsible for clotting. Grifols' antihemophilic factor is a concentrate containing factor VIII — one of the clotting factors (blood proteins)--- and is used for the treatment of Hemophilia A, a specific type of hemophilia.
  • Grifols' factor IX concentrate is used in the treatment of Hemophilia B, another specific type of hemophilia. Grifols' antihemophilic factor also contains von Willebrand factor – another important factor involved in normal clotting – and is used in the treatment of patients with von Willebrand's disease (VWD) undergoing surgical and/or invasive procedures in whom desmopressin (DDAVP®) is either ineffective or contraindicated. It is not indicated for patients with severe VWD (Type 3) undergoing major surgery.

Exposure to Infectious Agents

Grifols creates several hyperimmune globulin therapies to treat patients whose immune systems have been compromised or challenged by exposure to infectious agents. These therapies are concentrated, plasma-derived immunoglobulins, which provide rapid passive immunity immediately following an exposure. These therapies are intended to provide an immediate short-term immune response, and is then supplemented with  active immunization to provide long-term immunity. The combination of active and passive immunization optimizes the protection against infectious agents after exposure.
Grifols produces hyperimmunes for a variety of harmful and life-threatening diseases, including tetanus, rabies, hepatitis A& B, congenital rubella,  Rh hemolytic disease of the newborn (HDN) and Varicella (chickenpox).

Blood Loss Due to Shock or Trauma

Human albumin may sometimes be administered to restore blood levels and replace damaged blood proteins that occur as a result of severe burns, crushing injuries, surgical procedures or other serious medical events.

Human albumin constitutes about 55% of all plasma proteins. One of albumin's major roles is maintaining colloid osmotic or oncotic pressure, which is essential to keeping fluids in the bloodstream instead of leaking out into other human tissues. Providing albumin by intravenous administration can correct low albumin levels.